“For patients seeking noticeable results, whether it's improved skin texture, better sleep, enhanced metabolism or muscle ...

Onpattro is the first approved RNA interference therapy. In addition to first-mover advantage, Alnylam is positioned to expand its reach in ATTR amyloidosis with next-generation Amvuttra, which is ...

Discover how naturopathic physician Bill Caradonna, R.Ph., ND, uses homeopathic trigger point and subcutaneous injections to ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

The FDA has approved Skytrofa (lonapegsomatropin-tcgd) for the replacement of growth hormone in adults with GHD.

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie ...

An expert discusses how home administration of oncology drugs in the US faces significant logistical and reimbursement ...

KalVista Pharmaceuticals faces a shrinking HAE market, tough competition, and launch uncertainty despite FDA approval. Read ...

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I'm downgrading BMRN stock to Hold.

BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...